0
Abstract: Poster Presentations |

Eta-1 as a Staging Marker in Constrictive Bronchiolitis Obliterans FREE TO VIEW

Jennifer A. Svetlecic, MD*; Betty Herndon, PhD; Agostino Molteni, MD, PhD
Author and Funding Information

University of Missouri-Kansas City, Kansas City, MO


Chest


Chest. 2004;126(4_MeetingAbstracts):843S. doi:10.1378/chest.126.4_MeetingAbstracts.843S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Long term survival of lung transplantation is compromised by bronchiolitis obliterans (CBO). Other methods of inducing CBO, such as extended toxicant inhalation, produce histopathologic patterns seen with lung transplant CBO. Research has failed to discriminate early cellular markers that lead to CBO, which would provide clinical clues to disease progression. Our laboratory has produced both toxicant and transplant CBO models in the rat demonstrating small bronchiolar fibrosis preceded by peribronchiolar inflammation. We examined Eta-1 (Osteopontin) in these models, assessing this cytokine signal in order to identify the cellular correlate of the basic pathophysiologic mechanisms involved. Eta-1, a cytokine secreted by activated T lymphocytes, is reported to recruit and activate pulmonary macrophages, and could be an important mediator in CBO.

METHODS:  Rat models of inbred-mismatch tracheal transplant CBO were tested by whole lung BAL at 7 and 42 days. Toxicant-induced CBO (papaverine) was instituted in oubred SD rats by osmotic intratracheal pump delivery. Whole lung BAL was performed at 7 and 28 days. BAL from an intratracheal ARDS model was measured as control. Rat Eta-1 was measured by ELISA.

RESULTS:  Eta-1 was significantly elevated in toxicant-induced CBO at 7 days (p<0.02 ANOVA), with little chronic reactivity. Transplant-induced CBO exhibited no upregulation of Eta-1 in BAL at 7 or 42 days. The ARDS model demonstrated off-scale high Eta-1 at 7 and 14 days, disappearing by day 28, when chronic fibrosis begins.

CONCLUSION:  Early differences in BAL Eta-1 in the two CBO models suggest pathway differences to a similar final endpoint. Eta-1 has been reported in delayed-type immune responses early and in autoimmunity late. It appears to be neutrophil independent, but IL-12 related. These data suggest that a unique set of cell-mediated inflammatory cells and cytokines participate in early toxicant-induced CBO. Eta-1 could be useful in predicting CBO development.

CLINICAL IMPLICATIONS:  Markers of specific pathways to bronchial damage could be of immense importance to the early diagnosis of toxicant CBO. Further investigation continues to elucidate early immunologic markers of transplant induced CBO.

DISCLOSURE:  J.A. Svetlecic, None.

Wednesday, October 27, 2004

12:30 PM- 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543